<div id="readability-page-1"><div id="parent_top_div">Hyderabad-based biotechnology company BioVaram on Thursday said it has signed a MoU with Japan's Teijin Limited to collaborate on expanding usage of Regenerative Medicine products and Implantable medical devices in Japan and India. BioVaram, the University of Hyderabad incubated startup, is the brand name of the UR Advanced Therapeutics Pvt Ltd (URAT), a release said. The collaboration aims to expand the reach of Teijin Group's implantable medical devices and regenerative medicine products in India, while also introducing BioVaram's advanced product portfolio to the Japanese market, it said. &#34;Under the terms of the agreement, Teijin and BioVaram will explore the regulatory approval and commercialisation of SYNFOLIUM?, a cardiovascular repair patch by Teijin Medical Technologies Co, Ltd, in India,&#34; it said. The collaboration will open up opportunities for expanding use of Japan Tissue Engineering Co, Ltd's (part of the Teijin Group) regenerative medicine products in India. The agreement will also lead to the development and commercialisation in Japan of BioVaram technologies, including exosome-based diagnostics and therapeutics, Extracellular Matrix mimics, and bio-derived materials such as Type I atelocollagen. According to Takayuki Nakano, Mission Executive and General Manager, Regenerative Medicine &amp; Implantable Medical Device Division of Teijin Limited: &#34;The partnership with UR Advanced Therapeutics marks a highly significant step toward Teijin's global expansion in the fields of regenerative medicine and implantable medical devices.&#34; UR Advanced Therapeutics Founder and CEO Jaganmohan Reddy said the MoU with Teijin Limited reinforces BioVaram's vision to build transformative biotech innovations in India together with global partners. &#34;This partnership strengthens our capabilities in research, innovation, and scalable manufacturing of advanced tissue engineering products, while enabling Teijin to take BioVaram's products to global markets,&#34; he said.</div></div>

3401

总部位于海得拉巴的 BioVaram 与日本的帝人株式会社签署了一份谅解备忘录（MoU），旨在增强再生医学产品和可植入医疗设备在印度和日本的应用。此次合作将重点关注帝人心血管修复补丁在印度的监管批准和商业化，并将促进 BioVaram 技术在日本的引入。该合作伙伴关系旨在加强先进组织工程产品的研究和制造能力，标志着帝人在全球扩张努力中的重要一步

帝人公司与 BioVaram 签署协议，致力于提供下一代医疗解决方案